Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system.

The present invention identifies compounds that disrupt the interaction between anthrax proteins and LRP5/6 receptors, resulting in a reduction in anthrax toxicity. The compounds act to disrupt the intracellular transport of toxin complexes into a target cell. The present invention also provides methods for testing the effect of compounds on Wnt activity, through the use of in vitro experiments involving cells that have in at least one gene mutation involved in the Wnt pathway.

The present invention relates to methods for diagnosing and treating iron overload and iron deficiency.

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

The present invention relates to an inhibitor of R-spondin 2 and/or R-spondin 3 mediated bone morphogenetic protein (BMP) receptor inhibition for use in treating and/or preventing leukemia in a subject; and to methods, kits, combined preparations, and uses related thereto.

Disclosed herein are systems and methods for testing effects of simulated microgravity on muscle structures. The system includes a clinostat and an adapter that is receivable into the clinostat. The adapter includes a housing that defines at least one receptacle. The system further includes an assembly having a substrate and a plurality of fibrils deposited on the substrate. The plurality of fibrils comprise collagen and extend along an axis. The assembly is receivable into a first receptacle of the at least one receptacle. The plurality of fibrils can have myoblasts thereon. Operation of the clinostat simulates microgravity. Test substances can screened using the muscle structures to determine effects on myogenesis.